Document Detail


Preliminary evaluation of soluble IL-2 receptor and type III procollagen N-terminal aminopeptide in pleural fluid for differentiating tuberculous, carcinomatous and parapneumonic pleural effusions.
MedLine Citation:
PMID:  12421238     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of the study was to clarify the possibility of using pleural fluid levels of soluble IL-2 receptor (sIL-2R) and type III procollagen N-terminal aminopeptide (PIIIP) for differentiating tuberculous, carcinomatous and parapneumonic pleural effusions. METHODOLOGY: Fifty patients with pleural effusions were investigated retrospectively. The pleural effusions were due to tuberculosis (n = 11), carcinoma (n = 22), pneumonia (n = 9) and heart failure (n = 8). The concentrations of sIL-2R and PIIIP were measured in pleural effusion using commercially available kits. RESULTS: Soluble IL-2 receptor concentrations were highest in the patients with tuberculosis (6,856 +/- 3,212 U/mL), followed by those with carcinoma (4,680 +/- 1,872 U/mL), pneumonia (2,227 +/- 525 U/mL) and heart failure (1,439 +/- 244 U/mL). Significant differences were found between tuberculosis and carcinoma (P = 0.023), carcinoma and pneumonia (P = 0.015), and pneumonia and heart failure (P = 0.002) groups. Type III procollagen N-terminal aminopeptide concentrations were higher in the patients with tuberculosis (262.5 +/- 157.9 U/mL) and pneumonia (257.0 +/- 96.7 U/mL) than in those with carcinoma (48.0 +/- 27.7 U/mL) and heart failure (10.9 +/- 5.6 U/mL). Significant differences were found between tuberculosis and carcinoma (P < 0.001) and pneumonia and carcinoma (P < 0.001). To differentiate effusions, the cutoff points of sIL-2R (2,980 U/mL) and PIIIP (110.0 U/mL) were obtained from the highest concentration in the pneumonia group and in the carcinoma group, respectively. Using these criteria, the sensitivities for differentiating tuberculous, carcinomatous, and parapneumonic effusions were 90.9, 86.4 and 88.9%, respectively, with 100, 95 and 100% specificity, respectively. CONCLUSIONS: The simultaneous determination of sIL-2R and PIIIP concentrations in pleural effusions may be clinically useful in differentiating tuberculous, carcinomatous, and parapneumonic effusions. Further assessments are required to determine the broad clinical application of this assay.
Authors:
Shingo Harita; Naoyuki Nogami; Takeshi Kikuchi; Masayoshi Kibata
Related Documents :
16494928 - The mitogen-activated protein kinases (mapk) p38 and jnk are markers of tumor progressi...
18336278 - Malignant mesothelioma resistance to apoptosis: recent discoveries and their implicatio...
12607638 - Visceral pleura invasion and pleural lavage tumor cytology by lung cancer: a prospectiv...
12022548 - Diagnosis of visceral pleural invasion by lung cancer using intraoperative touch cytology.
16687488 - Intracellular hydrogen peroxide production is an upstream event in apoptosis induced by...
14654548 - Jun activation domain binding protein 1 expression is associated with low p27(kip1)leve...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Respirology (Carlton, Vic.)     Volume:  7     ISSN:  1323-7799     ISO Abbreviation:  Respirology     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-11-07     Completed Date:  2003-03-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9616368     Medline TA:  Respirology     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  311-5     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Chugoku Chuo Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama, Japan. s-harita@fukuyama.hiroshima.med.or.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Diagnosis, Differential
Female
Humans
Male
Middle Aged
Peptide Fragments / analysis*
Pleural Effusion / diagnosis*,  etiology
Pleural Effusion, Malignant / diagnosis*
Pneumonia, Pneumococcal / complications
Procollagen / analysis*
Receptors, Interleukin-2 / analysis*
Retrospective Studies
Solubility
Tuberculosis, Pulmonary / complications
Chemical
Reg. No./Substance:
0/Peptide Fragments; 0/Procollagen; 0/Receptors, Interleukin-2; 0/procollagen Type III-N-terminal peptide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular mechanisms underlying human beta-defensin-2 gene expression in a human airway cell line (L...
Next Document:  Addition of a 2-month low-dose course of levofloxacin to long-term erythromycin therapy in sinobronc...